Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Deerfield Capital Management Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Deerfield Capital Management ("DCM") is a global fixed-income investment adviser that has managed institutional, alternative accounts since 1993.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2014 | Nuo Therapeutics | Post-IPO Debt | 35M |
| 7/2019 | Frequency Therapeutics | Series C | 0 |
| 11/2018 | Mirum Pharmaceuticals | Series A | 120M |
| 7/2019 | Revolution Medicines | Series C | 100M |
| 4/2017 | SteadyMed Therapeutics | Post-IPO Equity | 0 |
| 7/2008 | PacBio | Series E | 100M |
| 9/2018 | Epic Sciences | Series E | 0 |
| 7/2018 | Alector | Series E | 133M |
| 2/2017 | Chondrial Therapeutics | Series A | 22.6M |
| 8/2010 | Raptor Pharmaceuticals | Post-IPO Equity | 0 |
| 10/2006 | Novare Surgical | Series D | 16M |
| 12/2019 | Quartet Health | Series D | 0 |
| 1/2019 | PQ Bypass | Private Equity Round | 0 |
| 6/2010 | Hanabiosciences | Private Equity Round | 100M |
| 6/2019 | Acutus Medical | Series D | 0 |
| 5/2010 | CardioMEMS | Venture Round | 0 |
| 10/2009 | CardioMEMS | Series F | 0 |
| 7/2016 | SteadyMed Therapeutics | Post-IPO Equity | 32M |
| 1/2018 | Braeburn | Debt Financing | 0 |
| 11/2018 | NeoChord | Series D | 25M |
| 8/2019 | GrayBug | Series C | 80M |
| 1/2019 | Cabaletta Bio | Series B | 0 |
| 1/2019 | Stelexis Therapeutics | Series A | 43M |
| 12/2016 | Vensun Pharmaceuticals | Series C | 22.5M |
| 7/2018 | MedAvail | Series D | 0 |
| 1/2019 | Itamar Medical | Post-IPO Equity | 0 |
| 6/2023 | Adaptive Phage Therapeutics | Series B | 12M |
| 6/2019 | Acutus Medical | Debt Financing | 70M |
| 10/2007 | Tengion | Series C | 33M |
| 6/2018 | Metacrine | Series C | 65M |
| 11/2016 | ConcertoCare | Venture Round | 30M |
| 5/2018 | Strata Oncology | Series B | 26M |
| 10/2014 | Invitae | Series F | 0 |
| 2/2017 | Rhythm Pharmaceuticals | Venture Round | 41M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 9/2012 | Foundation Medicine | Series B | 42.5M |
| 4/2007 | CymaBay Therapeutics | Series D | 32M |
| 1/2018 | Quartet Health | Series C | 45M |
| 5/2018 | FogPharma | Series B | 66M |
| 8/2018 | Orchard Therapeutics | Series C | 0 |
| 6/2018 | Appello Pharmaceuticals | Series A | 15.5M |
| 6/2009 | Arena Pharmaceuticals | Post-IPO Equity | 151.8M |
| 9/2018 | Allogene | Convertible Note | 0 |
| 3/2010 | BioSante Pharmaceuticals | Post-IPO Equity | 18M |
| 11/2017 | The Johns Hopkins University | Venture Round | 65M |
| 7/2013 | MannKind | Post-IPO Debt | 160M |
| 6/2010 | Arena Pharmaceuticals | Post-IPO Equity | 35.5M |
| 9/2014 | Aerie Pharmaceuticals | Post-IPO Equity | 125M |
| 5/2017 | Conventus Orthopaedics | Series C | 20M |
| 6/2023 | Adaptive Phage Therapeutics | Series B | 0 |
| 5/2023 | Ascend Gene &a; Cell Therapies | Series A | 0 |
| 4/2023 | Epic Sciences | Series G | 0 |
| 2/2022 | ConcertoCare | Series B | 0 |
| 12/2019 | Quartet Health | Series D | 0 |
| 8/2019 | GrayBug | Series C | 0 |
| 7/2019 | Frequency Therapeutics | Series C | - |
| 7/2019 | Revolution Medicines | Series C | 0 |
| 6/2019 | Acutus Medical | Series D | 0 |
| 6/2019 | Acutus Medical | Debt Financing | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
